Biomarin Pharmaceutical earnings were $657.2M for the trailing 12 months ending Jun 30, 2025, with 154.8% growth year over year. The latest BMRN earnings report on Jun 30, 2025 announced Q2 2025 earnings of $240.5M, up 29.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BMRN reported annual earnings of $426.9M, with 154.6% growth.
BMRN past earnings growth
How has BMRN's earnings growth performed historically?
Biomarin Pharmaceutical Earnings Reports & History FAQ
What were Biomarin Pharmaceutical's earnings last quarter?
On BMRN's earnings call on Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q2 2025 earnings per share (EPS) of $1.25, up 123.21% year over year. Total BMRN earnings for the quarter were $240.53 million. In the same quarter last year, Biomarin Pharmaceutical's earnings per share (EPS) was $0.56.
Is Biomarin Pharmaceutical profitable or losing money?
As of the last Biomarin Pharmaceutical earnings report, Biomarin Pharmaceutical is currently profitable. Biomarin Pharmaceutical's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $657.24 million, a 156.15% increase year over year.
What was BMRN's earnings growth in the past year?
As of Biomarin Pharmaceutical's earnings date in Invalid Date, Biomarin Pharmaceutical's earnings has grown 154.81% year over year. This is 123.09 percentage points higher than the US Biotechnology industry earnings growth rate of 31.72%. BMRN earnings in the past year totalled $657.24 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.